secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K/A
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-269359
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum acquires Bile Acid Business from Travere for up to $445M; H1 2023 revenue $53.6M, net income $13.6M
--------------------------------------------------------------------------------

- Acquired Chenodal and Cholbam assets for up to $445M ($210M upfront + up to $235M milestone payments).
- PIPE of 8M shares at $26.25 raised ~$202.2M net proceeds to fund acquisition.
- Acquired business had net product sales of $53.6M and net income of $13.6M for H1 2023 (unaudited).
- Pro forma combined financial statements filed; acquisition closed August 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523269359/0001193125-23-269359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523269359/d323300d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-269359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer